The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | CAPTIVATE: ibrutinib/venetoclax delivers high rates of uMRD in CLL
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, The Peter MacCallum Cancer Centre, Melbourne, Australia, describes the high rates of undetectable mesurable residual disease (uMRD) levels in the Phase II CAPTIVATE trial (NCT02910583), which looked at ibrutinib plus venetoclax for first-line therapy in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
